Gary S. Hogge - 10 Mar 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
SVP,Clinical & Medical Affairs
Signature
/s/ Grant Harbert, as Attorney-in Fact
Issuer symbol
LCTX
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
11 Mar 2022, 19:43:46 UTC
Previous filing
15 Feb 2022
Next filing
14 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (Right to Buy) Award $0 +450,000 $0.000000 450,000 10 Mar 2022 Common Shares 450,000 $1.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.